The Role of High-Level Isolation Units in Response to High-Consequence and Emerging Infectious Diseases: Experience of the German STAKOB Network.

Health Secur

Michaela Niebank, MD, is Head, Clinical Management and Infection Control, and Head, STAKOB office; and Agata Mikolajewska, MD, is a Staff Member and Coordinator, STAKOB office; both at the Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany. Stefan O. Brockmann, MD, is Head, Landesgesundheitsamt Referat 73, Ministerium für Soziales, Gesundheit und Integration Baden-Württemberg, Stuttgart, Germany. Torsten Feldt, MD, DTM, is an Infectious Disease Physician, Professor, and Head, Tropical Medicine Unit, Department of Gastroenterology, Hepatology and Infectious Diseases, Düsseldorf University Hospital, and Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. Björn-Erik Ole Jensen, MD, PD, DTM, is Coordinator, High-Level Isolation Unit, Department of Gastroenterology, Hepatology and Infectious Diseases, Düsseldorf University Hospital, and Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. Annette Jurke, PD, MSc, is Speaker, STAKOB, and Head; and Jennifer Schauer, PhD, is a Staff Member; both in the Infectious Disease Epidemiology Section, NRW Centre for Health, Bochum, Germany. Katja Rothfuss, MD, is Coordinator High-Level Isolation Unit, Department of Gastroenterology, Hepatology and Endocrinology, Robert-Bosch-Hospital, Stuttgart, Germany. Stefan Schmiedel, MD, PhD, DTMPH, is a Consultant, Infectious Disease and Tropical Medicine, and Coordinator, High Level Isolation Unit, University Medical Center Hamburg Eppendorf (UKE), Hamburg, Germany. Miriam Stegemann, MD, DTMH, is Head, Infectiology, Campus Virchow-Klinikum, Head of Antibiotic Stewardship, Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Peter Tinnemann, MD, PD, MPH, is Head, Gesundheitsamt Frankfurt, Frankfurt am Main, Germany. Alexander Uhrig, MD, is Medical Director, Medical Intensive Care Unit/High-level Isolation Unit, Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Timo Wolf, MD, PD, DTM, is Speaker, STAKOB, and Head, High-level Isolation Unit, Internal Medicine, Infectious Diseases, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.

Published: September 2024

This case study describes the experience of the German Permanent Working Group of Competence and Treatment Centers for High Consequence Infectious Diseases, known as STAKOB (). STAKOB brings together public health authorities (competence centers) and high-level isolation units (treatment centers) to collaborate on the clinical management of high-consequence infectious diseases (HCIDs) and emerging infectious diseases. The network is coordinated by the Robert Koch Institute, Germany's federal public health institute. The main tasks of STAKOB are to strengthen HCID clinical and public health management and increase expert knowledge on HCID and non-HCID emerging infectious diseases in Germany. STAKOB enables the exchange of knowledge and experiences; development of guidelines on infection prevention and control measures, clinical management, and therapy; and support for the World Health Organization and other outbreak responses internationally. The past years have shown how important the STAKOB network is for Germany-not only in providing critical care for HCID cases but also increasing capacity to support public health and clinical management of emerging infectious disease cases. However, maintaining several high-level isolation units in Germany requires a high commitment of financial, material, and human resources. Due to the rarity of HCID and emerging infectious disease events, maintaining the appropriate level of preparedness and ensuring sufficient investments is an ongoing struggle. Nevertheless, it is essential to have a network ready to react to HCID and non-HCID emerging infectious diseases in times of a changing biosecurity and infectious landscape.

Download full-text PDF

Source
http://dx.doi.org/10.1089/hs.2023.0156DOI Listing

Publication Analysis

Top Keywords

emerging infectious
24
infectious diseases
24
public health
16
high-level isolation
12
isolation units
12
clinical management
12
infectious
9
experience german
8
stakob network
8
treatment centers
8

Similar Publications

The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4 T cell count.

View Article and Find Full Text PDF

Background: Prenatally transmitted viruses can cause severe damage to the developing brain. There is unexplained variability in prenatal brain injury and postnatal neurodevelopmental outcomes, suggesting disease modifiers. Of note, prenatal Zika infection can cause a spectrum of neurodevelopmental disorders, including congenital Zika syndrome.

View Article and Find Full Text PDF

Event-based surveillance is crucial for the early detection and rapid response to potential public health risks. In recent years, social networking services (SNS) have been recognized for their potential role in this domain. Previous studies have demonstrated the capacity of SNS posts for the early detection of health crises and affected individuals, including those related to infectious diseases.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally due to HCC late diagnosis and limited treatment options. MiRNAs (miRNAs) emerged as potential biomarkers for various diseases, including HCC. However, the value of miRNA-101 as a serum biomarker for HCV-induced HCC has not been fully investigated.

View Article and Find Full Text PDF

Early noninvasive ventilation in general wards for acute respiratory failure: an international, multicentre, open-label, randomised trial.

Br J Anaesth

January 2025

Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

Background: The impact of noninvasive ventilation (NIV) managed outside the intensive care unit in patients with early acute respiratory failure remains unclear. We aimed to determine whether adding early NIV prevents the progression to severe respiratory failure.

Methods: In this multinational, randomised, open-label controlled trial, adults with mild acute respiratory failure (arterial oxygen partial pressure/fraction of inspiratory oxygen [Pao/FiO] ratio ≥200) were enrolled across 11 hospitals in Italy, Greece, and Kazakhstan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!